Working... Menu

Quality Assurance of Cognitive-behavioral Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03625024
Recruitment Status : Recruiting
First Posted : August 10, 2018
Last Update Posted : February 26, 2019
Information provided by (Responsible Party):
Benjamin Bohman, Karolinska Institutet

Brief Summary:
The study examines associations between competence in cognitive-behavioral therapy (CBT) and adherence to evidence-based generic CBT in therapists and treatment outcome in patients with depression or an anxiety disorder in psychiatric outpatient care.

Condition or disease Intervention/treatment
Depression, Anxiety Behavioral: Cognitive-behavioral therapy

Layout table for study information
Study Type : Observational
Estimated Enrollment : 85 participants
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Quality Assurance of Cognitive-behavioral Therapy: Adherence and Competence in Therapists and Treatment Outcome in Patients With Depression and Anxiety
Actual Study Start Date : August 1, 2018
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Intervention Details:
  • Behavioral: Cognitive-behavioral therapy
    Individual cognitive-behavioral therapy, including homework and behavioral change methods.

Primary Outcome Measures :
  1. Disorder-specific self-reported symptoms change instruments [ Time Frame: Change from baseline symptoms at 18 weeks ]
    Symptoms measures of depression or an anxiety disorder

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients in psychiatric outpatient care with depression or anxiety disorder.

Inclusion Criteria:

  • Primary diagnosis of major depression or an anxiety disorder (panic disorder, agoraphobia, social anxiety, generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder)

Exclusion Criteria:

  • Psychosis, bipolar disorder, eating disorder, substance use disorder, high risk of suicide, any simultaneous psychological treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03625024

Layout table for location contacts
Contact: Benjamin Bohman, PhD 72-244 49 00 ext +46

Layout table for location information
WeMind Psykiatri Recruiting
Stockholm, Sweden
Contact: Ida Viklund         
Sponsors and Collaborators
Karolinska Institutet
Layout table for investigator information
Principal Investigator: Benjamin Bohman, PhD Karolinska Institutet

Layout table for additonal information
Responsible Party: Benjamin Bohman, Dr, Karolinska Institutet Identifier: NCT03625024     History of Changes
Other Study ID Numbers: KI-2018/472-31/5
First Posted: August 10, 2018    Key Record Dates
Last Update Posted: February 26, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders